Entries by Thomas Gabrielczyk

Swedish TIRmed Pharma raises 4,3m€ against atopic dermatitis

/in /by

TIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis.

Switzerland needs more efforts in biomedicine

/in /by

In February 2025, the Federal Office of Public Health (FOPH) announced that the Masterplan in Biomedicine will be discontinued. This sends a troubling signal at a time of growing protectionism and potential trade conflicts. While other nations are actively collaborating with industry to secure the future of their pharmaceutical sectors, Switzerland is abandoning the only federal initiative aimed at improving conditions for biomedical research. The organisation scienceindustries calls for a renewed effort by the government to develop a new master plan.

Morphosys’ antibody still shining – for J&J

/in /by

The case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game and has now full ownership while expanding the indications further.

MoonLake in US$500m debt deal with Hercules Capital

/in /by

Swiss MoonLake Immunotherapeutics AG has secured up to US$500m in non-dilutive financing from life sciences debt specialist Hercules Capital to finance the potential 2027 launch of sonelokimab in hidradenitis suppurativa and clinical trials of the IL-17 dimerisation blocker in palmoplantar pustulosis and other inflammatory indications.

EU bioeconomy strategy enters crucial phase

/in /by

Europe’s decision on how to combine economic growth and decarbonisation in the future depends on the renewal of the EU bioeconomy strategy. The question is whether the EU will fall further behind globally or whether bioeconomy will become the EU’s growth engine.

New drug kills mosquitos by blood poisoning

/in /by

A drug named nitisinone, EU-approved for the treatment of metabolic diseases, also shows strong mosquito-killing properties. According to researchers headed by Lee Haines, it turns human blood toxic to Anopheles mosquitoes that transmit Plasmodium falciparum, the most deadly form of malaria.

Researchers crack the code of protein degradation

/in /by

Researchers at the Max Planck Institute of Biochemistry (MPIB) and MRC Laboratory of Molecular Biology in Cambridge have developed and patented the new UbiREAD technology, which decodes the complex ubiquitin code that marks target proteins for E3 ligase-mediated degradation in cells.